Holen Sie sich die Stockscreener-App
108.26
0.13%
0.1199
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$108.14
Offen:
$109.39
24-Stunden-Volumen:
2.18M
Relative Volume:
0.24
Marktkapitalisierung:
$188.18B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.50B
KGV:
29.13
EPS:
3.717
Netto-Cashflow:
$7.40B
1W Leistung:
-1.17%
1M Leistung:
-3.90%
6M Leistung:
-19.03%
1J Leistung:
-16.64%
1-Tages-Spanne:
$107.73
$110.31
1-Wochen-Bereich:
$107.73
$112.74
52-Wochen-Spanne:
$105.27
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.29 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
338.91 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.64 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.55 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.14 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories Stock (ISIN: US0028241000) Faces Pressure Amid Diagnostics Slowdown and Obesity - AD HOC NEWS
Benchmark reiterates Abbott stock rating on diabetes trial results - Investing.com
Abbott Launches ICRAS Tool to Assess Heart and Kidney Risks in Diabetes Patients - The Indian Practitioner
Intravenous (IV) Solutions Market Size to Reach USD 29.47 Billion by 2035 Due to the Increasing Prevalence of Chronic Diseases Globally | SNS Insider - GlobeNewswire Inc.
How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks - Yahoo Finance
Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin - MassDevice
Abbott (ABT) Showcases Positive Outcomes with FreeStyle Libre in Diabetes Management - GuruFocus
Abbott Laboratories $ABT Holdings Trimmed by Elevatus Welath Management - MarketBeat
Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & SuppliesDiversified Stocks - Yahoo Finance
Abbott’s Freedom To Work Plan And What It May Mean For NYSE ABT - simplywall.st
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management - Bolsamania
Diverging Views Emerge on Abbott Laboratories' Stock Outlook - AD HOC NEWS
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' - Investing News Network
Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' – Company Announcement - Financial Times
Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott - 24/7 Wall St.
Van ECK Associates Corp Has $50.42 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Mackenzie Financial Corp Buys 29,440 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Franklin Resources Inc. - MarketBeat
Vitamin D Testing Market Is Going to Boom |• Abbott • Roche Diagnostics • Siemens Healthineers - openPR.com
Capital World Investors Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Opening arguments begin in first Illinois trial against Abbott over its formula for premature babies - The Daily Gazette
Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects? - Yahoo Finance
MiniMed expands sensor portfolio in Europe with CE Mark for MiniMed™ 780G system with the Instinct sensor, made by Abbott - BioSpace
Capital International Sarl Buys 12,412 Shares of Abbott Laboratories $ABT - MarketBeat
Is It Time To Revisit Abbott Laboratories (ABT) After Recent Share Price Weakness? - simplywall.st
Abbott Laboratories (ABT) Announces $20 Billion Senior Notes Off - GuruFocus
Abbott Formula Linked To 'Horrible' Gut Disease, Ill. Jury Told - Law360
Abbott Laboratories Completes Major Senior Notes Offering - TipRanks
Four-Plaintiff Chicago Trial Opens Against Abbott Over Preterm Infant Formula - Law.com
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles (NYSE:ABT) - Seeking Alpha
Vinva Investment Management Ltd Has $10.21 Million Stake in Abbott Laboratories $ABT - MarketBeat
Russell Investments Group Ltd. Purchases 92,788 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Dundas Partners LLP - MarketBeat
Abbott Laboratories Pakistan : Board Meeting - marketscreener.com
B. Metzler seel. Sohn & Co. AG Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
First Trust Advisors LP Buys 810,684 Shares of Abbott Laboratories $ABT - MarketBeat
NEC Baby Formula Lawsuit & Settlement | March 2026 Update - Lawsuit Information Center
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Volatility - simplywall.st
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Faces Trial Over Claims Its Infant Formula Caused Bowel Disease in Premature Babies - The Indian Practitioner
Trial over Abbott Laboratories’ formula for premature babies set to begin this week - Times West Virginian
Crossmark Global Holdings Inc. Purchases 12,373 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Labs to face trial on infant formula - The Economic Times
Trial over Abbott Laboratories’ formula for premature babies set to begin in Chicago this week - The Daily Gazette
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Daywatch: Trial over Abbott Laboratories’ formula for premature babies set to begin - Chicago Tribune
Abbott set to face trial over claims premature infant formula caused deadly disease - Reuters
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):